Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Omega 3 Fatty Acids and Age-Related Macular Degeneration (AMD)

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: April 2015

Workgroups: Vision Workgroup

Age‐related macular degeneration (AMD) is an eye condition that affects the retina (light‐sensitive tissue at the back of the eye) and can lead to vision loss. In this Cochrane systematic review, researchers looked at whether Omega 3 fatty acids can help prevent or slow the progression of AMD. They found that taking omega 3 supplements for periods up to 5 years did not reduce the rate of progression from early to advanced AMD or reduce vision loss, compared to a placebo.

Read more about this resource

Objectives related to this resource (1)

Reduce vision loss from age-related macular degeneration — V‑07
Baseline only

Suggested Citation

1.

Lawrenson JG, Evans JR. (2015). Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD010015. DOI: 10.1002/14651858.CD010015.pub3.